Filter Results
:
(922)
Show Results For
-
All HBS Web
(922)
- People (2)
- News (63)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (645)
Show Results For
-
All HBS Web
(922)
- People (2)
- News (63)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (645)
John A. Deighton
John Deighton is The Harold M. Brierley Professor of Business Administration Emeritus at Harvard Business School. He is an authority on consumer behavior and marketing, with a focus on digital and direct marketing. He teaches in the area of Big Data in Marketing,... View Details
Keywords:
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry;
e-commerce industry
- 01 Dec 2019
- News
Remix
community after their respective accusations against Clarence Thomas and Mike Tyson. It’s one of the factors that helps explain why women of color report sexual assault at rates far below that of white women and a major force behind Dixon’s decision to leave the View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
tilted towards old age than annuities. Several advantages of this are discussed, including some that may explain why tontines have proven popular with consumers in the past. Download the paper: http://www.hbs.edu/research/pdf/09-121.pdf PublicationsWhere Is the...
View Details
Keywords:
Martha Lagace
- Web
Globalization - Faculty & Research
Dilemmas: Novo Nordisk’s Weight Loss DrugsBy: Joseph L. Badaracco, Tom Quinn and John Schultz April 2024 | Case | Faculty Research Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in...
View Details
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side...
View Details
Keywords:
Sean Silverthorne
- Web
Stat Plus | Baker Library | Bloomberg Center | Harvard Business School
Pharmaceuticals Database AttributesCategories Industry Specific Databases Industry Specific News Keywords health tech industry overview medical...
View Details
- Web
Informa (In Vivo, MedTech Insight, Scrip) | Baker Library | Bloomberg Center | Harvard Business School
platform. Related Resources Medical Devices Pharmaceuticals Database AttributesCoverageIn Vivo - latest 3 months; MedTech - Most recent 1 year(s) 6 month(s) available; Start-up?Categories Industry Specific...
View Details
- July 2009 (Revised May 2010)
- Case
Pfizer: Letter from the Chairman (A)
By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to...
View Details
Keywords:
Decision Choices and Conditions;
Corporate Accountability;
Corporate Governance;
Annual Reports;
Business and Shareholder Relations;
Value Creation;
Pharmaceutical Industry;
United States
Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
- Web
Vault | Baker Library | Bloomberg Center | Harvard Business School
Hotels Investment Banking Pharmaceuticals Retail & Luxury Goods Sustainability Technology Database AttributesCategories Career Guides Career Resources General Industry Information Keywords View Details
- Web
Recruiting Partners - Health Care
Kearney, Inc. Abbott ABILITY Network, Inc. Abpro Accolade Adimab, Inc. Advance Technological Radiology PA Advantage Healthcare Inc. Advocates Aetna Agilent Technologies AGION Technologies Aledade Alkermes Allen Institute for Brain Science Allergan Almata Health Alnylam...
View Details
- December 2017 (Revised January 2018)
- Case
Alltech
By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech...
View Details
Keywords:
Alltech;
United States;
Agribusiness;
Agriculture;
Animal;
Animal Agriculture;
Animal Feed;
Livestock;
Family Business;
Vertical Integration;
Strategy;
Growth;
Feed Additives;
Feed Supplements;
Kentucky;
Growth Strategy;
Family Businesses;
Animal-Based Agribusiness;
Acquisition;
Business Growth and Maturation;
Business Model;
Change Management;
Trends;
Governance;
Entrepreneurship;
Growth and Development;
Intellectual Property;
Leadership;
Management;
Markets;
Organizational Culture;
Private Ownership;
Science;
Quality;
Risk and Uncertainty;
Research;
Sales;
Agriculture and Agribusiness Industry;
Agriculture and Agribusiness Industry;
United States;
Kentucky;
Brazil;
China
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
- March 2023
- Case
Roche: ESG and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Health Industry;
Health Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: ESG and Access to Healthcare." Harvard Business School Case 123-075, March 2023.
- 17 Jan 2008
- Working Paper Summaries
Competition in Modular Clusters
- December 2019
- Case
The Business of Pain: Johnson & Johnson and the Promise of Opioids
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or...
View Details
Keywords:
Opioids;
Addiction;
Stakeholder Capitalism;
Business and Stakeholder Relations;
Product Launch;
Decision Making;
Ethics;
Social Issues;
Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.
- 01 Sep 2007
- News
Alfred D. Chandler Jr. Remembered
Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based View Details
Joey Ryu
Joey (Won Jung) Ryu is a doctoral student in the Strategy unit at Harvard Business School. Her primary interests are strategic management, economics of innovation and entrepreneurship. Prior to joining HBS, Joey recieved her master's degree from Cornell University...
View Details
- October 2022
- Case
Cost Plus Drugs
By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies....
View Details
Keywords:
Business Ventures;
Decision Making;
Entrepreneurship;
Ethics;
Health;
Markets;
Social Enterprise;
Society;
Strategy;
Health Care and Treatment;
Business Divisions;
Factories, Labs, and Plants;
Health Industry;
Health Industry;
United States;
Texas
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The...
View Details
Keywords:
Business Model;
Change Management;
Decision Choices and Conditions;
Cost Management;
Price;
Product Marketing;
Product Launch;
Product Development;
Risk and Uncertainty;
Health Industry;
Health Industry
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it...
View Details
Keywords:
Patents;
Lawsuits and Litigation;
Rights;
Competitive Strategy;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- May 1998 (Revised May 1999)
- Case
Biopure Corp.
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood...
View Details
Keywords:
Segmentation;
Marketing Strategy;
Engineering;
Budgets and Budgeting;
Sales;
Transformation;
Markets;
Debates;
Product Launch;
Pharmaceutical Industry
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)